COVID-19 (Coronavirus) Update: Vaccine Updates | COVID-19 Information | Visitor Guidelines

A Phase 2 Randomized, Multicenter, Double-Blind Study of the Glutaminase Inhibitor Telaglenastat with Pembrolizumab and Chemotherapy Versus Placebo with Pembrolizumab and Chemotherapy in First-Line, Metastatic KEAP1/NRF2-Mutated, Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)

Protocol No
CALITHERA-CX-839-014-KEAPSAKE
Principal Investigator
Smitha Menon
Phase
II
Summary
The purpose of this study is to determine the amount (dose) of Telaglenastat that is safe and tolerable when given together with the recommended treatment regimen of Pembrolizumab, Carboplatin, and Pemetrexed. Researchers also want to determine if the combination of standard drugs with Telaglenastat is more active against 1LKEAP1/NRF-2 Mutated NS-NSCLC than the standard drugs alone.
Description
A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated,NS-NSCLC
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Sub Category